Larimar completes FDA submission seeking accelerated approval of nomlabofusp
LRMR•Larimar Therapeutics completed its FDA application seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, targeting potential U.S. approval by mid-2027 and a third-quarter launch if approved.
1. FDA application completed
Larimar Therapeutics completed its FDA application seeking accelerated approval of nomlabofusp for Friedreich’s ataxia. The company targets potential U.S. approval by mid-2027 and plans a launch in the third quarter if approved.
